Breast Cancer Research

official impact factor 5.79

This article is part of the supplement: VIII Madrid Breast Cancer Conference: Latest Advances in Breast Cancer

Poster presentation

A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer

OC Freedman, E Amir, G Dranitsaris, M Dowsett, DEC Cole, H Kahn, F O'Malley, S Verma and M Clemons

Breast Cancer Research 2009, 11(Suppl 1):P33 doi:10.1186/bcr2316

No comments have yet been made on this article.

Post a comment